Akhil Chopra

6.3k total citations
27 papers, 750 citations indexed

About

Akhil Chopra is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Akhil Chopra has authored 27 papers receiving a total of 750 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 11 papers in Hepatology. Recurrent topics in Akhil Chopra's work include Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Colorectal Cancer Treatments and Studies (7 papers). Akhil Chopra is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Colorectal Cancer Treatments and Studies (7 papers). Akhil Chopra collaborates with scholars based in Singapore, United States and Hong Kong. Akhil Chopra's co-authors include Winnie Yeo, Jeffrey Anderson, Theodore H. Welling, Bruno Sangro, Anthony B. El-Khoueiry, Ignacio Melero, Todd S. Crocenzi, Christine Marie Dela Cruz, Thomas Cheung Yau and Lixin Lang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Hepatology.

In The Last Decade

Akhil Chopra

25 papers receiving 737 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Akhil Chopra Singapore 14 350 343 214 139 133 27 750
Antonio Cubillo Gracián Spain 15 439 1.3× 308 0.9× 136 0.6× 125 0.9× 119 0.9× 30 697
Yabing Cao China 15 350 1.0× 182 0.5× 135 0.6× 189 1.4× 87 0.7× 52 811
Oxana V. Makarova‐Rusher United States 10 334 1.0× 269 0.8× 109 0.5× 232 1.7× 85 0.6× 17 707
Hideki Ueno Japan 14 389 1.1× 160 0.5× 140 0.7× 132 0.9× 83 0.6× 44 706
Christine Marie Dela Cruz United States 11 421 1.2× 448 1.3× 109 0.5× 147 1.1× 162 1.2× 13 694
Petros Fessas United Kingdom 8 341 1.0× 168 0.5× 133 0.6× 58 0.4× 55 0.4× 14 529
Xu-Dong Qu China 16 203 0.6× 501 1.5× 156 0.7× 155 1.1× 124 0.9× 40 839
Imane El Dika United States 13 214 0.6× 178 0.5× 109 0.5× 69 0.5× 86 0.6× 30 573
Giorgio Frega Italy 16 459 1.3× 155 0.5× 235 1.1× 107 0.8× 98 0.7× 55 865
Jian-Ming Xu China 12 578 1.7× 176 0.5× 341 1.6× 41 0.3× 152 1.1× 15 818

Countries citing papers authored by Akhil Chopra

Since Specialization
Citations

This map shows the geographic impact of Akhil Chopra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akhil Chopra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akhil Chopra more than expected).

Fields of papers citing papers by Akhil Chopra

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akhil Chopra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akhil Chopra. The network helps show where Akhil Chopra may publish in the future.

Co-authorship network of co-authors of Akhil Chopra

This figure shows the co-authorship network connecting the top 25 collaborators of Akhil Chopra. A scholar is included among the top collaborators of Akhil Chopra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akhil Chopra. Akhil Chopra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
El-Khoueiry, Anthony B., Jörg Trojan, Tim Meyer, et al.. (2023). Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040. Annals of Oncology. 35(4). 381–391. 27 indexed citations
2.
Yau, Thomas, Chiun Hsu, Tae‐You Kim, et al.. (2019). Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. Journal of Hepatology. 71(3). 543–552. 187 indexed citations
3.
4.
Verma, Akash, Dessmon Y.H. Tai, Ai Ching Kor, et al.. (2018). Outcome of advanced lung cancer with central airway obstructionversuswithout central airway obstruction. ERJ Open Research. 4(2). 173–2017. 13 indexed citations
5.
Choo, Su Pin, Thomas Yau, Chih‐Hung Hsu, et al.. (2017). Efficacy and safety of nivolumab in asian patients with advanced hepatocellular carcinoma (HCC): Subanalysis of the CheckMate 040 Study. Annals of Oncology. 28. x57–x58. 1 indexed citations
6.
Chopra, Akhil, et al.. (2017). Comparative Study of Psychiatric Manifestations among Type I and Type II Diabetic Patients. Indian Journal of Psychological Medicine. 39(3). 342–346. 13 indexed citations
7.
Chopra, Akhil, et al.. (2017). Povidone-iodine for the management of oral mucositis during cancer therapy. Oncology Reviews. 11 indexed citations
8.
Crocenzi, Todd S., Anthony B. El-Khoueiry, Thomas Cheung Yau, et al.. (2017). Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.. Journal of Clinical Oncology. 35(15_suppl). 4013–4013. 68 indexed citations
9.
Melero, Ignacio, Anthony B. El-Khoueiry, Thomas Yau, et al.. (2017). Efficacy and safety of nivolumab in patients with advanced hepatocellular carcinoma analyzed by patient age: A sub-analysis of the CheckMate 040 study. Annals of Oncology. 28. iii139–iii139. 2 indexed citations
10.
Melero, Ignacio, Bruno Sangro, Thomas Cheung Yau, et al.. (2017). Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.. Journal of Clinical Oncology. 35(4_suppl). 226–226. 21 indexed citations
11.
Verma, Akash, Akhil Chopra, Lavina Bharwani, et al.. (2016). Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma. Current Drug Discovery Technologies. 13(2). 68–76. 15 indexed citations
12.
Verma, Akash, Akhil Chopra, & John Abisheganaden. (2016). Effectiveness of EGFR-tyrosine kinase inhibitors (TKI) versus EGFR-TKIs plus talc pleurodesis in preventing recurrence of malignant pleural effusion (MPE) in advanced lung adenocarcinoma.. Journal of Clinical Oncology. 34(15_suppl). e21684–e21684. 1 indexed citations
13.
El-Khoueiry, Anthony B., Bruno Sangro, Thomas Cheung Yau, et al.. (2016). Phase I/II safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of the CheckMate-040 dose escalation study.. Journal of Clinical Oncology. 34(15_suppl). 4012–4012. 24 indexed citations
14.
Verma, Akash, Albert Yick Hou Lim, Dessmon Y.H. Tai, et al.. (2015). Timeliness of Diagnosing Lung Cancer. Medicine. 94(29). e1216–e1216. 19 indexed citations
15.
El-Khoueiry, Anthony B., Ignacio Melero, Todd S. Crocenzi, et al.. (2015). Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.. Journal of Clinical Oncology. 33(18_suppl). LBA101–LBA101. 154 indexed citations
16.
Buecheler, Jakob W., Christopher B. Howard, Christopher J. de Bakker, et al.. (2014). Development of a protein nanoparticle platform for targeting EGFR expressing cancer cells. Journal of Chemical Technology & Biotechnology. 90(7). 1230–1236. 12 indexed citations
17.
Haaland, Benjamin, Akhil Chopra, Sanchalika Acharyya, André P. Fay, & Gilberto Lopes. (2014). Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma. BMC Cancer. 14(1). 592–592. 6 indexed citations
18.
Chopra, Akhil, et al.. (2014). Subglottic Extramedullary Plasmacytoma With Light Chain Multiple Myeloma Masquerading as Adult-Onset Asthma. Journal of Voice. 28(3). 394.e1–394.e4. 2 indexed citations
19.
Chopra, Akhil, Benjamin Haaland, & Gilberto Lopes. (2013). Comparative effective analysis between enzalutamide and abiraterone in the treatment of metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 31(6_suppl). 217–217. 4 indexed citations
20.
Ku, Geoffrey Y., Akhil Chopra, & Gilberto Lopes. (2010). Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity. Lung Cancer. 70(2). 223–225. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Antonio Cubillo Gracián Breakdown of academic impact, for papers by Yabing Cao Breakdown of academic impact, for papers by Oxana V. Makarova‐Rusher Breakdown of academic impact, for papers by Hideki Ueno Breakdown of academic impact, for papers by Christine Marie Dela Cruz Breakdown of academic impact, for papers by Petros Fessas Breakdown of academic impact, for papers by Xu-Dong Qu Breakdown of academic impact, for papers by Imane El Dika Breakdown of academic impact, for papers by Giorgio Frega Breakdown of academic impact, for papers by Jian-Ming Xu
Rankless by CCL
2026